title: Identification and Functional Characterization of a Cryptococcus neoformans UPC2 Homolog.
abstract: Azoles are currently the most widely used class of antifungal drugs clinically, and are effective for treating fungal infections. Target site of azoles is ergosterol biosynthesis in fungal cell membrane, which is absent in the mammalian host. However, the development of resistance to azole treatments in the fungal pathogen has become a significant challenge. Here, we report the identification and functional characterization of a UPC2 homolog in the human pathogen Cryptococcus neoformans. UPC2 plays roles in ergosterol biosynthesis, which is also affected by the availability of iron in Saccharomyces cerevisiae and Candida albicans. C. neoformans mutants lacking UPC2 were constructed, and a number of phenotypic characteristics, including antifungal susceptibility and iron utilization, were analyzed. No differences were found between the mutant phenotypes and wild type, suggesting that the role of C. neoformans UPC2 homolog may be different from those in S. cerevisiae and C. albicans, and that the gene may have a yet unknown function.
authors: Department of Biotechnology, Chung-Ang University, Ansung 456-756, Korea.
authors: Nam Kyun
authors: NK
authors: Kim
authors: Kyunghwan
authors: K
authors: Han
authors: Won Hee
authors: WH
authors: Jung
keywords: Antifungal drugs; Cryptococcus neoformans; Ergosterol biosynthesis; Fungal pathogenesis; Iron
references: J Biol Chem. 1996 Jul 12;271(28):16927-33
references: 8663358
references: J Biol Chem. 2008 Mar 28;283(13):8318-30
references: 18227070
references: Curr Opin Microbiol. 2000 Aug;3(4):354-8
references: 10972493
references: J Infect Dis. 1993 Jan;167(1):186-90
references: 8418165
references: J Bacteriol. 1993 Mar;175(5):1405-11
references: 8444802
references: J Biol Chem. 2010 May 7;285(19):14823-33
references: 20231268
references: Eukaryot Cell. 2003 Aug;2(4):655-63
references: 12912884
references: Eukaryot Cell. 2005 Jun;4(6):1079-87
references: 15947200
references: Yeast. 1998 Dec;14(16):1471-510
references: 9885152
references: Infect Immun. 2007 Jun;75(6):2729-39
references: 17371865
references: EMBO J. 1997 May 15;16(10):2576-89
references: 9184205
references: Infect Immun. 1995 Aug;63(8):3131-6
references: 7622240
references: PLoS Biol. 2006 Nov;4(12):e410
references: 17121456
references: PLoS Pathog. 2008 Feb 8;4(2):e45
references: 18282105
references: J Med Vet Mycol. 1996 Jul-Aug;34(4):289-91
references: 8873890
references: Clin Microbiol Rev. 1999 Oct;12(4):501-17
references: 10515900
references: J Bacteriol. 1982 Jun;150(3):1212-20
references: 6804439
references: Eukaryot Cell. 2009 Oct;8(10):1511-20
references: 19700638
references: Microbiology (Reading). 2007 Jan;153(Pt 1):29-41
references: 17185532
references: Antimicrob Agents Chemother. 2005 May;49(5):1745-52
references: 15855491
references: Mol Cell Biol. 2008 Feb;28(4):1326-37
references: 18070921
references: Cell Microbiol. 2008 Feb;10(2):277-84
references: 18042257
references: Microbiology (Reading). 2002 Aug;148(Pt 8):2607-2615
references: 12177355
references: Clin Microbiol Rev. 1995 Oct;8(4):515-48
references: 8665468
references: Mol Microbiol. 2006 Nov;62(4):1090-101
references: 17040492
references: Antimicrob Agents Chemother. 2006 Nov;50(11):3597-606
references: 16954314
references: Curr Opin Infect Dis. 2003 Apr;16(2):91-6
references: 12734441
references: J Steroid Biochem. 1990 Aug 14;36(5):505-6
references: 2214765
references: Mol Cell Biol. 2001 Oct;21(19):6395-405
references: 11533229
references: Fungal Genet Biol. 2004 Nov;41(11):973-81
references: 15465386
references: J Exp Med. 1996 Aug 1;184(2):377-86
references: 8760791